Corporate
News release
TopTOKYO, JAPAN - May 21, 2019 - Terumo Corporation (TSE: 4543) today announced that it has appointed an associate of Terumo Europe NV as the newest "Terumo Fellow". Terumo instituted the Terumo Fellow program to recognize associates who have made outstanding contributions leading to innovation in healthcare, and in the technology, research, clinical, and regulatory affairs, of Terumo Group. Terumo created the program in 2016 and this is the sixth individual appointed.
Terumo will recognize Fien Aerts, Vice President Regulatory, Complaint and Vigilance of Terumo EMEA as the newest Terumo Fellow. She joined Terumo in 1983, and is well acknowledged for establishing the foundation of Terumo's quality management system and regulatory affairs. Ms. Aerts has been the leading figure for Terumo's first drug-eluting stent to acquire a CE mark, and her great leadership continues to take impact globally. Her unchanging pursuit for top quality, and her expertise in healthcare regulation has contributed to the registration of numerous products Terumo provides today.
Terumo holds "Quality - committed to excellence" as one of the Core Values, which are shared by and connect Terumo associates worldwide. To ensure safety and reliability, we will continue to contribute to healthcare, by encouraging technology, research, clinical and regulatory affairs advancement.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.